<DOC>
	<DOCNO>NCT01512862</DOCNO>
	<brief_summary>Proteinuria marker chronic kidney disease ( CKD ) progression , also marker cardiovascular disease death . In previous study , active vitamin D deficiency associate cardiovascular risk factor albuminuria , diabetes mellitus , low glomerular filtration rate ( GFR ) . And calcitriol show preventive effect progressive glomerular damage renal ablation model . Calcitriol , active form vitamin D ( 1,25-dihydroxyvitamin-D3 ) , commonly use treatment secondary hyperparathyroidism patient advance chronic kidney disease . Therefore , objective study evaluate anti-proteinuric effect calcitriol non-diabetic kidney disease patient . They treat calcitriol placebo 24 week observe 24 week treatment . Proteinuria , renal function , serum urinary inflammatory marker , adverse event monitor .</brief_summary>
	<brief_title>Anti-proteinuric Effect Calcitriol Non-diabetic Kidney Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Nondiabetic kidney disease patient age 1970 year MDRD GFR ≥ 30 mL/min/1.73m2 Patients residual urine protein/creatinine ratio &gt; 200 mg/g Adequate blood pressure control treat systolic blood pressure &lt; =140 diastolic &lt; =90 mmHg RAS inhibitor 3 month Normotensive patient untreated RAS inhibitor Serum intact PTH 35500 mg/dL serum calcium le 10.2 mg/dL Patients treat vitamin D within 3 month prior sign inform consent form Patients nephroticrange proteinuria ( 24 hour urine protein &gt; 3.5 g/24 hr ) Patients rapidly progressive glomerulonephritis Patients require renal replacement therapy immediately Hypercalcemia ( uncorrected serum calcium level &gt; 10.2 mg/dL ) within 3 month Malignant hypertension Heart failure ( New York Heart Association [ NYHA ] functional class II IV LVEF le 40 % ) Severe chronic obstructive lung disease Decompensated liver disease Known allergy hypersensitivity vitamin D Current treatment steroid and/or immunosuppressive agent No active primary malignancy require treatment limit survival ≤ 2 year History noncompliance medical regimen Inability give inform consent cooperate researcher ( e.g. , psychiatric disorder )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Calcitriol</keyword>
	<keyword>Off-label</keyword>
</DOC>